Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903866 | 0.99 | PSMB5 (0.51) | PSMB5PIK3CATLR8HSD11B1MAPKAPK2 | |
| SCHEMBL29903858 | 0.99 | PSMB5 (0.51) | PSMB5PIK3CATLR8HSD11B1MAPKAPK2 | |
| SCHEMBL29903844 | 0.99 | PSMB5 (0.51) | PSMB5PIK3CATLR8HSD11B1MAPKAPK2 | |
| SCHEMBL30440085 | 0.96 | PSMB5 (0.56) | PSMB5PIK3CATLR8HSD11B1MAPKAPK2 | |
| SCHEMBL30439681 | 0.90 | PIK3CA (0.55) | PSMB5PIK3CATLR8MAPKAPK2AKT1 | |
| SCHEMBL30439659 | 0.88 | PIK3CA (0.50) | PSMB5PIK3CATLR8AKT1 | |
| SCHEMBL29903869 | 0.88 | PSMB5 (0.48) | PSMB5PIK3CATLR8HSD11B1GPR3 | |
| SCHEMBL30439822 | 0.87 | DHODH (0.43) | PSMB5PIK3CATLR8AKT1 | |
| SCHEMBL30440002 | 0.86 | DHODH (0.45) | PSMB5PIK3CATLR8 | |
| SCHEMBL30439475 | 0.84 | PIK3CA (0.57) | PSMB5PIK3CAMAPKAPK2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | FABP4, FABP1, FABP3 | PSMB5 4189/4885PIK3CA 3770/4885TLR8 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.